Cash/Burn From SEC Filing For Period: 

Q3 '19

SUPN

Supernus Pharmaceuticals

Supernus is a specialty pharmaceuticals company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company's lead products, Oxtellar XR® and Trokendi XR®, are for the treatment of epilepsy. Supernus is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in patients with attention deficit hyperactivity disorder (ADHD) and SPN-812 for the treatment of ADHD.

Cash

$296.7M

Burn Rate

-

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Trokendi XR

Migraine Prevention

Approved

Oxtellar XR

Partial Seizure

Approved

SPN-812

ADHD

PDUFA

11/8/2020

SPN-810

IA in Attention Deficit Hyperactivity Disorder (ADHD)

Phase 3

1Q 2020

SPN-604

Bipolar

Phase 2

SPN-809

Depression

Phase 2

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon